AU Patent

AU2016204879B2 — CDK Inhibitors

Assigned to Pharmacosmos Holding AS · Expires 2018-02-01 · 8y expired

What this patent protects

H:\trm\Interwoven\NRPortbl\DCC\TRN\04851741 .docx-13/07/2016 Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

USPTO Abstract

H:\trm\Interwoven\NRPortbl\DCC\TRN\04851741 .docx-13/07/2016 Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2016204879B2
Jurisdiction: AU
Classification: —
Expires: 2018-02-01
Drug substance claim: No
Drug product claim: No
Assignee: Pharmacosmos Holding AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.